Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free IRON Stock Alerts

Disc Medicine (IRON) Competitors

Disc Medicine logo
$67.59 -0.05 (-0.07%)
Closing price 04:00 PM Eastern
Extended Trading
$67.54 -0.05 (-0.07%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IRON vs. ARWR, AXSM, PRAX, ABVX, and PCVX

Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX), Abivax (ABVX), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Arrowhead Pharmaceuticals currently has a consensus target price of $84.20, indicating a potential upside of 12.37%. Disc Medicine has a consensus target price of $104.80, indicating a potential upside of 55.05%. Given Disc Medicine's higher possible upside, analysts plainly believe Disc Medicine is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Arrowhead Pharmaceuticals has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$829.45M12.65-$1.63M$1.5348.97
Disc MedicineN/AN/A-$212.18M-$5.99N/A

Arrowhead Pharmaceuticals has a net margin of 18.54% compared to Disc Medicine's net margin of 0.00%. Arrowhead Pharmaceuticals' return on equity of 35.64% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals18.54% 35.64% 13.61%
Disc Medicine N/A -32.80%-30.19%

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Disc Medicine. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 13 mentions for Disc Medicine. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat Disc Medicine's score of 0.48 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats Disc Medicine on 12 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Axsome Therapeutics currently has a consensus target price of $251.89, indicating a potential upside of 12.93%. Disc Medicine has a consensus target price of $104.80, indicating a potential upside of 55.05%. Given Disc Medicine's higher possible upside, analysts plainly believe Disc Medicine is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.90
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Axsome Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Axsome Therapeutics has higher revenue and earnings than Disc Medicine. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M17.97-$183.17M-$3.69N/A
Disc MedicineN/AN/A-$212.18M-$5.99N/A

Disc Medicine has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -28.69%. Disc Medicine's return on equity of -32.80% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-28.69% -232.61% -25.84%
Disc Medicine N/A -32.80%-30.19%

In the previous week, Axsome Therapeutics had 31 more articles in the media than Disc Medicine. MarketBeat recorded 44 mentions for Axsome Therapeutics and 13 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.48 beat Axsome Therapeutics' score of 0.38 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
13 Very Positive mention(s)
11 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 22.3% of Axsome Therapeutics shares are held by company insiders. Comparatively, 3.6% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Axsome Therapeutics beats Disc Medicine on 9 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Disc Medicine's return on equity of -32.80% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -58.74% -53.54%
Disc Medicine N/A -32.80%-30.19%

Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.6% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Praxis Precision Medicines currently has a consensus target price of $590.78, indicating a potential upside of 77.25%. Disc Medicine has a consensus target price of $104.80, indicating a potential upside of 55.05%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Disc Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
5 Strong Buy rating(s)
3.00
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/A-$303.27M-$13.46N/A
Disc MedicineN/AN/A-$212.18M-$5.99N/A

In the previous week, Disc Medicine had 6 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 13 mentions for Disc Medicine and 7 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.10 beat Disc Medicine's score of 0.48 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Disc Medicine beats Praxis Precision Medicines on 8 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Abivax?

Abivax (NASDAQ:ABVX) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

In the previous week, Disc Medicine had 6 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Disc Medicine and 7 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat Disc Medicine's score of 0.48 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Disc Medicine's return on equity of -32.80% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -146.43% -88.69%
Disc Medicine N/A -32.80%-30.19%

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$5.37N/A
Disc MedicineN/AN/A-$212.18M-$5.99N/A

Abivax currently has a consensus target price of $137.15, indicating a potential upside of 10.80%. Disc Medicine has a consensus target price of $104.80, indicating a potential upside of 55.05%. Given Disc Medicine's higher probable upside, analysts plainly believe Disc Medicine is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

47.9% of Abivax shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.6% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Disc Medicine beats Abivax on 9 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Vaxcyte?

Disc Medicine (NASDAQ:IRON) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Vaxcyte's return on equity of -25.88% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Disc MedicineN/A -32.80% -30.19%
Vaxcyte N/A -25.88%-23.85%

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Disc Medicine is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Disc MedicineN/AN/A-$212.18M-$5.99N/A
VaxcyteN/AN/A-$766.63M-$5.62N/A

Disc Medicine presently has a consensus target price of $104.80, suggesting a potential upside of 55.05%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 54.69%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Disc Medicine is more favorable than Vaxcyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Disc Medicine had 3 more articles in the media than Vaxcyte. MarketBeat recorded 13 mentions for Disc Medicine and 10 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Disc Medicine's score of 0.48 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 3.6% of Disc Medicine shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Vaxcyte beats Disc Medicine on 7 of the 13 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRON vs. The Competition

Export
MetricDisc MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.58B$3.40B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-11.2838.8529.0428.48
Price / SalesN/A155.54476.4860.89
Price / CashN/A57.8827.6236.52
Price / Book3.467.039.676.67
Net Income-$212.18M$23.62M$3.55B$332.64M
7 Day Performance0.49%3.67%1.70%2.01%
1 Month Performance3.70%7.17%5.62%9.19%
1 Year Performance39.07%67.04%34.42%39.59%

Disc Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRON
Disc Medicine
2.4441 of 5 stars		$67.59
-0.1%		$104.80
+55.1%		N/A$2.58BN/AN/A30
ARWR
Arrowhead Pharmaceuticals
2.6361 of 5 stars		$70.15
-4.7%		$83.78
+19.4%		N/A$9.82B$1.09B45.85400
AXSM
Axsome Therapeutics
3.17 of 5 stars		$185.00
-1.3%		$218.06
+17.9%		N/A$9.46B$638.50MN/A380
PRAX
Praxis Precision Medicines
3.3965 of 5 stars		$321.92
-2.7%		$590.78
+83.5%		N/A$8.97B$8.55MN/A110
ABVX
Abivax
3.1719 of 5 stars		$109.87
-1.8%		$137.15
+24.8%		N/A$8.71BN/AN/A61

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel